✦ LIBER ✦

Phase I trial of indicine-N-oxide on two dose schedules

✍ Scribed by Sarah Taylor; Robert J. Belt; Charles D. Haas; Barth Hoogstraten

Publisher: John Wiley and Sons
Year: 1983
Tongue: English
Weight: 350 KB
Volume: 51
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19830601)51:11<1988::aid-cncr2820511105>3.0.co;2-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ifosfamide, paclitaxel, and cisplatin fo

Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract : Final report of a Phase II trial evaluating two dosing schedules

✍ Dean F. Bajorin; John A. McCaffrey; Paul M. Dodd; Susan Hilton; Madhu Mazumdar; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

## BACKGROUND. A combination regimen of ifosfamide, paclitaxel, and cisplatin (ITP), recycled every 4 weeks, was reported in the treatment of previously untreated patients with advanced transitional cell carcinoma (TCC). This study sought to examine ITP at 3-week intervals to assess its feasibility

Phase I trial of low dose N-phosphonacet

Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas

✍ Bach Ardalan; Antonio Ucar; Rajender Reddy; Alan S. Livingstone; Arnold Markoe; 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 450 KB 👁 2 views

A Phase I clinical trial of ixabepilone

A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

✍ Sen H. Zhuang; Manish Agrawal; Maureen Edgerly; Susan Bakke; Herb Kotz; Paul Tha 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract ## BACKGROUND The epothilones are a novel class of microtubule‐stabilizing agents. Ixabepilone (BMS‐247550; NSC 710428) is a semisynthetic analog of the natural product epothilone B. The authors conducted a Phase I study by administering ixabepilone to patients as a 1‐hour intravenous

Prospective randomized open-label multic

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis

✍ Daniel C. Baumgart; Stephan R. Targan; Axel U. Dignass; Lloyd Mayer; Gert van As 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

## Background: Visilizumab is a humanized igg(2) monoclonal anti-cd3 antibody. we evaluated its safety and dose response in severe intravenous steroid-refractory ulcerative colitis (uc). ## Methods: In all, 104 patients were treated. in stage i, 73 patients were randomly assigned to receive intra

A randomised double-blind placebo-contro

A randomised double-blind placebo-controlled trial of the impact of high-dose statins on the ischaemia-reperfusion injury in elective AAA repair

✍ M. N. A. Abdul Rahman; M. Heng; L. Madden; J. Greenman; P. T. McCollum; I. C. Ch 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 1 views

## 4 VSGBI abstracts (→ = +0•56, p = 0•003 and → = +0•38, p < 0•0•001, respectively). RCF had an independent inverse correlation with bk-PWV (→ = -0•01, p = 0•01). Systolic blood pressure showed an independent positive correlation with ba-PWV only after adjustment for other biomarkers (→ = +0•1, p

A phase I trial to assess the value of r

A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (r-MetHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL)

✍ G. M. Smith; J. A. Child; M. H. Cullen; N. P. Bailey; C. M. Woodruffe; J. Fletch 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

In a multi-centre phase I study we investigated the possibility of reducing the interval between courses of standard CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m', vincristine 2 mgs day 1, and prednisolone 40mglm' days 1-8) from 21 days to 15 days and then 10 days using granulocyte colony s